Search
Guselkumab
go.drugbank.com/drugs/DB11834ApprovedInvestigationalGuselkumab is a human immunoglobulin G1 lambda (IgG1λ) monoclonal antibody that selectively blocks interleukin-23. … Developed by Janssen, the subcutenous injection form of guselkumab was approved in July 2017 under the market name Tremfya for the treatment of adult patients with moderate-to-severe plaque psoriasis.
Products: TREMFYA 100MG/ML SOLUTION FOR INJECTION, Tremfya One-Press 100mg/ml Solution for InjectionNeratinib
go.drugbank.com/drugs/DB11828ApprovedInvestigationalApproval was granted to Puma Biotechnology Inc. for the tradename Nerlynx. Neratinib is currently under investigation for use in many other forms of cancer. … Neratinib was approved in July 2017 for use as an extended adjuvant therapy in Human Epidermal Growth Factor Receptor 2 (HER2) positive breast cancer.
Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexTrastuzumab deruxtecan
go.drugbank.com/drugs/DB14962ApprovedInvestigationalTrastuzumab deruxtecan is a HER2-directed antibody attached to a topoisomerase inhibitor that is approved for use in certain types of treatment-resistant HER2-positive cancers.
Products: ENHERTU POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/VIALLixisenatide
go.drugbank.com/drugs/DB09265ApprovedInvestigationalLixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist used in the treatment of type II diabetes mellitus (T2DM).
Mixtures: Soliqua SoloStar 100units/mL+33mcg/mL solution for injection in a pre-filled pen, SOLIQUA SOLUTION FOR INJECTION IN A PRE-FILLED PEN 100UNITS/ML + 50MCG/MLSynonyms: des-38-proline-exendine-4 (Heloderma suspectum)-(1-39)-peptidylpenta-L-lysyl-L-lysinamideDeferiprone
go.drugbank.com/drugs/DB08826ApprovedInvestigationalThalassemias are a type of hereditary anaemia due a defect in the production of hemoglobin. As a result, erythropoiesis, the production of new red blood cells, is impaired. … Deferiprone is an oral iron chelator used as a second line agent in thalassemia syndromes when iron overload from blood transfusions occurs.
Categories: Compounds used in a research, industrial, or household settingProducts: GPO-L-One Tablet 500mgGlipizide
go.drugbank.com/drugs/DB01067ApprovedInvestigational[L6712] Because sulfonylureas require functional pancreatic beta cells for their therapeutic effectiveness, sulfonylureas are more commonly used for early-stage type 2 diabetes when there is no progressed … According to the 2018 Clinical Practice Guidelines by Diabetes Canada, sulfonylurea drugs are considered a second-line glucose-lowering therapy following metformin.
Chlorpropamide
go.drugbank.com/drugs/DB00672ApprovedWithdrawnChlorpropamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). … Chlorpropamide is not recommended for the treatment of NIDDM as it increases blood pressure and the risk of retinopathy (UKPDS-33).
Aceclidine
go.drugbank.com/drugs/DB13262ApprovedAceclidine is a cholinergic muscarinic agonist which began marketing in Europe in the 1970s for the treatment of glaucoma. … [A274278] Aceclidine was approved the US FDA in July 2025 for the treatment of adult patients with presbyopia.[L53768]
Doxazosin
go.drugbank.com/drugs/DB00590ApprovedInvestigationalDoxazosin is an alpha-1 antagonist used for the treatment of benign prostatic hypertrophy (BPH) symptoms and hypertension. … [A180661] Because of its long-lasting effects, doxazosin can be administered once a day.[A180649] It is marketed by Pfizer and was initially approved by the FDA in 1990.[L7285]
Categories: Antihypertensive Agents Indicated for HypertensionProducts: DOXAZOSIN 1 COR 1A PHARMA, DOXAZOSIN 2 COR 1A PHARMA